DiaCarta’s Novel XNA Technology is a Game Changer for Sanger

PLEASANTON, Calif.: PLEASANTON, Calif., Sept. 9, 2021 /PRNewswire/ -- DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced the publication of a study entitled "Target Enrichment Enhances the Sensitivity of Sanger Sequencing for BRAF V600 Mutation Detection" in bioRxiv (https://www.biorxiv.org/content/10.1101/2021.08.14.456349v1)...

Click to view original post